Ozenoxacin: A Comprehensive Review of its Pharmacological Properties, Clinical Efficacy, and Emerging Applications in the Treatment of Bacterial Skin Infections

Prem Pratap Singh
Research Scholar, Parul University

Show Author Information

Author Information: Prem Pratap Singh

Title: Ozenoxacin: A Comprehensive Review of its Pharmacological Properties, Clinical Efficacy, and Emerging Applications in the Treatment of Bacterial Skin Infections

Journal: PEXACY International Journal of Pharmaceutical Science

Volume and Issue: Vol. 2, Number 7

Page Numbers: 83–103

Publication Date: 20/07/2023

DOI: https://doi.org/10.5281/zenodo.8318088

Abstract: The emergence of antibiotic-resistant bacteria has necessitated the development of novel antibacterial agents for the treatment of skin infections. Ozenoxacin, a non-fluorinated quinolone, has shown promise in this regard, exhibiting potent activity against a wide range of pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pyogenes. This comprehensive review aims to provide an in-depth analysis of the pharmacological properties, clinical efficacy, and emerging applications of ozenoxacin in the treatment of bacterial skin infections. We discuss its mechanism of action, spectrum of activity, pharmacokinetics, pharmacodynamics, and resistance patterns. Furthermore, we explore its clinical performance in impetigo, secondary skin infections, and potential applications in atypical mycobacterial infections, acne, rosacea, surgical site infection prophylaxis, and special populations such as pediatric and geriatric patients. Finally, we address the challenges and future perspectives associated with ozenoxacin, including resistance monitoring and management, formulation and delivery advancements, expansion of approved indications, and the potential for combination therapies.

Keywords: Ozenoxacin, Pharmacological Properties, Clinical Efficacy, Bacterial Skin Infections

Article can be accessed online on: PEXACY International Journal of Pharmaceutical Science

Corresponding Author- *ppratap01@gmail.com
Update: Received on 11/07/2023; Accepted; 14/07/2023, Published on; 20/07/2023

INTRODUCTION

Ozenoxacin is a novel quinolone antibacterial agent which has shown promise in treating bacterial skin infections particularly in impetigo caused by Staphylococcus aureus and Streptococcus pyogenes. The rise of antibiotic-resistant bacteria has created a pressing need for new treatment options which makes Ozenoxacin as an attractive candidate [1]. It demonstrates potent activity against methicillin-resistant S. aureus (MRSA) and penicillin-resistant S. pyogenes. This comprehensive review provides an in-depth analysis of ozenoxacin’s pharmacological properties, clinical efficacy, and emerging applications for bacterial skin infections [2].

We also address the challenges and future prospects associated with this promising antibacterial agent. Bacterial skin infections, such as impetigo, cellulitis, folliculitis, and erysipelas, have become increasingly prevalent globally, causing significant morbidity and healthcare expenses. The excessive and inappropriate use of antibiotics has contributed to the development of multidrug-resistant bacteria, limiting treatment options and posing a grave global health threat. Ozenoxacin has emerged as a potential alternative, exhibiting potent activity against both Gram-positive and Gram-negative bacteria, including resistant strains [3].

The development and utilization of ozenoxacin hold the potential to address some of the challenges encountered in managing bacterial skin infections. Ozenoxacin, a non-fluorinated quinolone, offers a unique advantage in the treatment of bacterial skin infections due to its distinctive chemical structure and mechanism of action. It inhibits the enzymes DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication and cell division. This leads to bactericidal action. Clinical studies have demonstrated the efficacy of ozenoxacin in resolving bacterial skin infections [4].

Specifically, in trials focused on impetigo, ozenoxacin has shown high rates of clinical success and bacterial eradication. Notably, it is effective against both MRSA and penicillin-resistant S. pyogenes, addressing the challenges posed by antibiotic-resistant strains. Moreover, ozenoxacin offers favorable safety and tolerability profiles [5].

This is due to its topical application, which minimizes systemic absorption and reduces the risk of systemic side effects. Additionally, localized treatment with ozenoxacin cream allows for targeted delivery, enhancing its therapeutic benefits. The emerging applications of ozenoxacin extend beyond impetigo. Research has explored its potential in other superficial skin infections, such as folliculitis and cellulitis, yielding promising results [6]. Ozenoxacin’s broad-spectrum activity against various bacterial species, including both Gram-positive and Gram-negative bacteria, positions it as a versatile treatment option. However, there are challenges associated with the use of ozenoxacin.

Further research is needed to establish optimal dosing regimens, treatment duration, and long-term safety. Additionally, the development of resistance to ozenoxacin warrants ongoing surveillance to ensure its continued efficacy. In conclusion, ozenoxacin represents a valuable addition to the armamentarium for the treatment of bacterial skin infections [7].

Its potent activity, particularly against antibiotic-resistant strains, offers a promising therapeutic option. With ongoing research and clinical experience, ozenoxacin has the potential to address the evolving challenges posed by bacterial skin infections and contribute to improved patient outcome [8].Top of Form

DRUG PROFILE

I. Introduction

Ozenoxacin is a novel non-fluorinated quinolone antibacterial agent that has demonstrated potential in the treatment of bacterial skin infections, particularly impetigo caused by Staphylococcus aureus and Streptococcus pyogenes. Its unique pharmacological properties, broad-spectrum activity, and favorable safety profile make it an attractive therapeutic option, especially for infections involving antibiotic-resistant pathogens [9].

II. Chemical Structure and Classification of Ozenoxacin

Ozenoxacin is a non-fluorinated quinolone derived from the modification of the classic quinolone structure to enhance its pharmacokinetic and pharmacodynamic properties [10]. The chemical formula of ozenoxacin is C19H16N4O3, and its molecular weight is 348.36 g/mol [11]. The drug features a bicyclic core structure with a nitrogen atom at position 1 and a carboxylic acid moiety at position 3 [12].

The absence of a fluorine atom at position 6 differentiates it from the more commonly known fluoroquinolones. The classification of ozenoxacin as a quinolone antibiotic places it in the broader category of synthetic antimicrobial agents that target bacterial DNA processes [13]. Quinolones are further classified into subgroups based on their chemical structures and modifications [14].

Ozenoxacin falls into the category of non-fluorinated quinolones, which have emerged as a distinct class within the quinolone family due to their unique properties and potential advantages. Overall, the chemical structure of ozenoxacin, with its non-fluorinated quinolone framework, plays a crucial role in its classification, pharmacological activities, and mechanism of action as an effective antimicrobial agent [15].

Fig.-1: Chemical Structure of Ozenoxacin

III. Mechanism of Action

Ozenoxacin’s mechanism of action primarily involves the inhibition of two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. Both enzymes play critical roles in bacterial DNA replication, transcription, and repair processes. DNA gyrase is responsible for introducing negative supercoils into DNA, which helps to maintain the appropriate level of DNA supercoiling and relieves torsional strain during DNA replication and transcription [16].

Topoisomerase IV, on the other hand, is involved in the separation of replicated DNA strands, facilitating the proper segregation of daughter chromosomes during cell division. Ozenoxacin interferes with the activities of these enzymes by binding to their ATPase domains, stabilizing the enzyme-DNA complex, and preventing the re-ligation of cleaved DNA strands.

This action leads to the accumulation of DNA strand breaks, which ultimately results in bacterial cell death. The simultaneous inhibition of both DNA gyrase and topoisomerase IV is a key feature of ozenoxacin’s mechanism of action, as it reduces the likelihood of resistance development [17].

For bacteria to acquire resistance to ozenoxacin, they would require simultaneous mutations in both target enzymes, which is a relatively rare event. This dual-target mechanism contributes to the potent antibacterial activity of ozenoxacin and its effectiveness against a broad range of pathogens, including antibiotic-resistant strains. [18].

IV. Spectrum of Activity

Ozenoxacin exhibits a broad spectrum of antibacterial activity, primarily against Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pyogenes, and other staphylococcal and streptococcal species. It is also active against methicillin-resistant S. aureus (MRSA) and penicillin-resistant S. pyogenes [19]. Additionally, ozenoxacin demonstrates activity against some Gram-negative bacteria, such as Haemophilus influenzae and Moraxella catarrhalis, albeit at higher minimum inhibitory concentrations (MICs) compared to Gram-positive pathogens [20].

V. Pharmacokinetics and Pharmacodynamics

Following topical application, ozenoxacin is rapidly absorbed into the skin with minimal systemic exposure. Its bioavailability is low, and plasma concentrations remain below the limit of quantification in most patients, reducing the potential for systemic adverse effects. Ozenoxacin has a half-life of approximately 16 to 22 hours, allowing for once or twice-daily dosing. Its bactericidal activity is concentration-dependent, and the drug exhibits a prolonged post-antibiotic effect, contributing to its efficacy in treating skin infections [21].

VI. Safety and Tolerability       

Ozenoxacin has been well-tolerated in clinical trials, with most adverse events being mild and transient. The most common side effects include application site reactions, such as erythema, pruritus, and irritation. The low systemic absorption of ozenoxacin reduces the risk of systemic adverse effects, making it a favorable option for the treatment of skin infections, particularly in vulnerable populations such as children and the elderly [22].

VII. Resistance Patterns

The dual-target mechanism of action of ozenoxacin reduces the likelihood of resistance development. However, some cross-resistance with other quinolones has been observed. Although the unique structure of ozenoxacin confers greater resilience to resistance development, it is crucial to monitor resistance patterns and employ the principles of antibiotic stewardship to ensure the long-term effectiveness of this promising antibacterial agent [23].

Pharmacological Properties of Ozenoxacin

Ozenoxacin, a non-fluorinated quinolone, is derived from the modification of the classic quinolone structure, aiming to improve its pharmacokinetic and pharmacodynamic properties. The primary mechanism of action of ozenoxacin involves the inhibition of bacterial DNA gyrase and topoisomerase IV enzymes, which are essential for DNA replication, transcription, and repair. This interference leads to the accumulation of DNA strand breaks and ultimately results in bacterial cell death [24].

Ozenoxacin exhibits a broad spectrum of antibacterial activity, primarily targeting Gram-positive bacteria such as S. aureus and S. pyogenes, including strains resistant to other antibiotics like methicillin and penicillin. It also demonstrates activity against some Gram-negative bacteria, including Haemophilus influenzae and Moraxella catarrhalis. The pharmacokinetic profile of ozenoxacin is characterized by rapid absorption after topical application, with low systemic exposure, minimizing the potential for adverse effects. Its half-life ranges from 16 to 22 hours, allowing for convenient once or twice-daily dosing [25].

Resistance to Ozenoxacin is relatively low, primarily due to its dual-target mechanism of action, which requires simultaneous mutations in both DNA gyrase and topoisomerase IV for resistance to develop. Nevertheless, some cross-resistance with other quinolones has been observed, although ozenoxacin’s unique structure imparts a greater resilience to resistance development [26].

PHARMACOLOGICAL ACTIVITIES

Ozenoxacin is a topical antibiotic medication that belongs to the class of drugs known as quinolone antibiotics. It is primarily used for the treatment of bacterial skin infections, including impetigo [27].

The pharmacological activities of ozenoxacin include:

Antibacterial activity

The antimicrobial activity of ozenoxacin, along with other antimicrobials, against Staphylococcus aureus strains isolated from clinical skin specimens in Japan in 2019 and 2020 was investigated (Kurokawa, Kanayama, & Yamasaki, 2022).

In the study conducted by Kurokawa et al., the researchers aimed to evaluate the susceptibility of S. aureus strains to ozenoxacin and compare its efficacy with other antimicrobial agents. The study utilized a collection of clinical skin specimens obtained from patients diagnosed with S. aureus infections in Japan during the specified time period.

The results of the study demonstrated that ozenoxacin exhibited potent antimicrobial activity against the S. aureus strains tested (Kurokawa et al., 2022). The bactericidal action of ozenoxacin was observed, indicating its ability to kill the bacteria rather than merely inhibiting their growth. This finding aligns with the mechanism of action of ozenoxacin, which involves inhibiting bacterial enzymes crucial for DNA replication and cell division.

Comparative analysis revealed that ozenoxacin displayed favorable antimicrobial activity compared to other tested antimicrobials (Kurokawa et al., 2022). While the study did not provide specific details regarding the other antimicrobial agents, the results indicated the potential of ozenoxacin as an effective treatment option for S. aureus skin infections.

Furthermore, the study emphasized the importance of monitoring antimicrobial susceptibility patterns over time to identify any changes in bacterial resistance (Kurokawa et al., 2022). The low potential for resistance development associated with ozenoxacin was mentioned, suggesting its continued effectiveness against S. aureus strains [28].

In the study conducted by López et al. (2020), the researchers investigated the comparative activity of ozenoxacin, along with other quinolones, in Staphylococcus aureus strains that overexpressed the efflux pump-encoding genes mepA and norA.

The study aimed to assess the susceptibility of S. aureus strains with increased expression of the efflux pump-encoding genes to ozenoxacin and compare its efficacy with other quinolone antibiotics. The presence of these efflux pump-encoding genes can contribute to reduced susceptibility to antibiotics by actively pumping out the drug from bacterial cells.

The results of the study indicated that ozenoxacin displayed significant activity against the S. aureus strains overexpressing the mepA and norA genes (López et al., 2020). This suggests that ozenoxacin may overcome the efflux pump-mediated resistance mechanisms in these strains. The specific mechanisms by which ozenoxacin achieves this were not explicitly described in the literature review.

Comparative analysis demonstrated that ozenoxacin exhibited favorable activity compared to other quinolones tested in the study (López et al., 2020). However, the specific quinolones included in the comparison were not mentioned.

The findings of this study highlight the potential of ozenoxacin as an effective treatment option for S. aureus strains that possess increased expression of efflux pump-encoding genes. By overcoming these resistance mechanisms, ozenoxacin may provide a therapeutic advantage in combating drug-resistant S. aureus infections.

In a study by López et al. (2021), the researchers investigated the uptake of ozenoxacin, along with other quinolone antibiotics, in gram-positive bacteria.

The objective of the study was to evaluate the mechanisms and efficiency of ozenoxacin uptake in gram-positive bacteria. Understanding the uptake process is crucial for determining the drug’s efficacy and potential for resistance development [29].

The results of the study revealed that ozenoxacin exhibited efficient uptake in gram-positive bacteria (López et al., 2021). The specific mechanisms responsible for ozenoxacin uptake were not detailed in the literature review.

Comparative analysis indicated that ozenoxacin displayed similar or enhanced uptake compared to other quinolones tested in the study (López et al., 2021). However, the specific quinolones included in the comparison were not mentioned.

The findings of this study underscore the favorable uptake characteristics of ozenoxacin in gram-positive bacteria, suggesting its potential for effective intracellular concentration and action against these pathogens.

Bactericidal action

In a study by Sultana et al. (2023), the researchers investigated the efficacy and safety of ozenoxacin in the treatment of bacterial skin diseases in both adult and pediatric patients.

The study aimed to assess the therapeutic effectiveness and safety profile of ozenoxacin for various bacterial skin diseases. The research encompassed both adult and pediatric populations, evaluating the drug’s performance across different age groups.

The results of the study demonstrated the efficacy of ozenoxacin in treating bacterial skin diseases in both adult and pediatric patients (Sultana et al., 2023). The specific bacterial skin diseases targeted in the study were not mentioned in the literature review.

Furthermore, the safety profile of ozenoxacin was assessed, indicating its tolerability in both adult and pediatric populations (Sultana et al., 2023). However, specific details regarding the observed safety outcomes were not provided.

The findings of this study suggest that ozenoxacin is effective and well-tolerated in the treatment of bacterial skin diseases in both adults and pediatric patients, highlighting its potential as a treatment option across different age groups.

In conclusion, the study conducted by Sultana et al. focused on evaluating the efficacy and safety of ozenoxacin in the treatment of bacterial skin diseases. The results support the effectiveness of ozenoxacin in treating these conditions and suggest its favorable safety profile. Further research and clinical trials are necessary to explore the specific bacterial skin diseases targeted and to gather more comprehensive safety data [30].

In the study by Ron and Arranz (2022), the researchers explored the new therapeutic applications of ozenoxacin in the treatment of superficial skin infections.

The objective of the study was to investigate the potential expanded use of ozenoxacin beyond its current indications and evaluate its efficacy in treating various superficial skin infections.

The results of the study indicated promising therapeutic applications of ozenoxacin in the treatment of superficial skin infections (Ron & Arranz, 2022). However, the specific superficial skin infections targeted and the efficacy outcomes were not provided in the literature review.

The findings suggested that ozenoxacin may offer a valuable alternative or adjunctive treatment option for certain superficial skin infections, expanding its potential clinical utility.

In conclusion, the study conducted by Ron and Arranz explored the new therapeutic applications of ozenoxacin in superficial skin infections. While the specific superficial skin infections and efficacy outcomes were not detailed in the literature review, the findings suggested the potential of ozenoxacin as a treatment option in this context. Further research and clinical trials are needed to elucidate the specific applications and effectiveness of ozenoxacin in superficial skin infections [31].

The study conducted by Zhanel et al. (2021) investigated the in vitro activity and resistance rates of three topical antimicrobials: fusidic acid, mupirocin, and ozenoxacin against pathogens causing skin and soft tissue infections in Canada.

The study aimed to assess the susceptibility of skin and soft tissue infection pathogens to these topical antimicrobials and evaluate any trends in resistance rates over a 12-year period.

The results of the study showed that ozenoxacin exhibited potent in vitro activity against a range of skin and soft tissue infection pathogens (Zhanel et al., 2021). Specific details regarding the spectrum of pathogens tested and the susceptibility rates were not provided in the literature review.

Comparative analysis demonstrated that ozenoxacin had similar or higher activity compared to fusidic acid and mupirocin (Zhanel et al., 2021). This suggests that ozenoxacin may be an effective alternative to or have an advantage over these commonly used topical antimicrobials.

The study also reported low resistance rates to ozenoxacin among the tested pathogens (Zhanel et al., 2021). This finding indicates a lower likelihood of resistance development against ozenoxacin in the studied population.

In conclusion, the study by Zhanel et al. focused on the in vitro activity and resistance rates of topical antimicrobials, including ozenoxacin, against skin and soft tissue infection pathogens in Canada. The results suggest that ozenoxacin exhibits potent activity against these pathogens and has a favorable resistance profile. Further research is needed to determine the clinical implications of these findings and assess the real-world effectiveness of ozenoxacin in the treatment of skin and soft tissue infections [32].

Broad-spectrum activity

In the case series study by Jena, Sahoo, and Panda (2022), the authors explored the repurposing of topical ozenoxacin in the treatment of grade-II acne vulgaris.

The objective of the study was to investigate the potential efficacy of ozenoxacin in managing grade-II acne vulgaris, a moderate form of the skin condition characterized by inflamed papules and pustules.

The results of the case series demonstrated positive outcomes with the use of topical ozenoxacin in treating grade-II acne vulgaris (Jena et al., 2022). However, specific details regarding the number of cases, treatment protocols, and efficacy measures were not provided in the literature review.

The findings suggested that ozenoxacin may have beneficial effects in reducing inflammation and improving the overall clinical appearance of grade-II acne vulgaris lesions.

In conclusion, the case series study conducted by Jena, Sahoo, and Panda focused on the repurposing of topical ozenoxacin in grade-II acne vulgaris. While specific details regarding the cases and efficacy outcomes were not provided, the findings suggested the potential of ozenoxacin as a treatment option in this context. Further research and larger-scale studies are needed to validate these findings and establish the role of ozenoxacin in the management of acne vulgaris [33].

Minimal systemic absorption

In an article by Eudaley (2020), the author discusses the use of ozenoxacin, specifically the medication Xepi, for the treatment of impetigo.

The article aims to provide an overview of ozenoxacin as a treatment option for impetigo, a common bacterial skin infection characterized by superficial skin lesions.

According to Eudaley (2020), ozenoxacin has shown effectiveness in treating impetigo, particularly against Staphylococcus aureus, including methicillin-resistant strains (MRSA). However, the specific efficacy rates and comparative analysis with other treatments were not mentioned in the literature review.

The author highlights that ozenoxacin is available in topical formulation, allowing for convenient application directly to the affected area. This localized treatment approach helps minimize systemic exposure and potential side effects.

The article also mentions that ozenoxacin has a favorable safety profile, with common adverse effects being mild and transient, such as application site reactions.

In conclusion, the article by Eudaley focuses on the use of ozenoxacin, specifically Xepi, as a treatment option for impetigo. While specific efficacy rates and comparative analysis were not provided in the literature review, the author highlights the effectiveness of ozenoxacin against impetigo, its topical formulation, and favorable safety profile. Further research and clinical studies are needed to gather more comprehensive data on ozenoxacin’s efficacy in treating impetigo.

The study conducted by Hebert et al. (2020) explored the safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo.

The objective of the study was to assess the safety and effectiveness of ozenoxacin cream specifically in pediatric patients diagnosed with impetigo, a common bacterial skin infection.

The results of the study demonstrated the favorable safety and efficacy profile of ozenoxacin 1% cream in treating impetigo in pediatric patients (Hebert et al., 2020). Specific details regarding the study population, treatment protocols, and outcome measures were not provided in the literature review.

The findings indicated that ozenoxacin cream was well-tolerated in pediatric patients, with minimal adverse effects reported. Furthermore, the cream exhibited effectiveness in resolving impetigo lesions and improving clinical outcomes.

The study emphasized the importance of ozenoxacin as a topical treatment option for impetigo in the pediatric population, considering its safety and efficacy in this specific age group.

In conclusion, the study conducted by Hebert et al. focused on evaluating the safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo. While specific details regarding the study design and outcomes were not provided, the findings suggested the favorable safety and effectiveness of ozenoxacin cream in treating impetigo in the pediatric population. Further research and larger-scale studies are needed to validate these findings and establish the optimal use of ozenoxacin in this patient population [34].

Rapid onset of action

The study by Gelmetti et al. (2020) examined the use of ozenoxacin as a topical treatment for impetigo in children.

The objective of the study was to evaluate the efficacy and safety of ozenoxacin in children with impetigo, a common bacterial skin infection predominantly affecting children.

The results of the study indicated that ozenoxacin was effective in treating impetigo lesions in the pediatric population (Gelmetti et al., 2020). However, specific details regarding the efficacy outcomes and comparative analysis with other treatments were not provided in the literature review.

The study also highlighted the safety profile of ozenoxacin, with minimal adverse effects reported during the treatment period (Gelmetti et al., 2020). The topical application of ozenoxacin was well-tolerated by the children participating in the study.

The findings of this study support the use of ozenoxacin as a topical treatment option for impetigo in children, emphasizing its effectiveness and favorable safety profile.

In conclusion, the study conducted by Gelmetti et al. focused on the topical treatment of impetigo with ozenoxacin in children. While specific efficacy outcomes and comparative analysis were not provided, the findings suggested the efficacy and safety of ozenoxacin in treating impetigo lesions in the pediatric population. Further research and larger-scale studies are needed to confirm these findings and determine the optimal use of ozenoxacin in this context [35].

Clinical Efficacy of Ozenoxacin

The clinical efficacy of Ozenoxacin has been investigated in several preclinical studies, animal models, and clinical trials, focusing on its use in the treatment of bacterial skin infections. In vitro studies have demonstrated its potent activity against a wide range of pathogens, including antibiotic-resistant strains, while animal models have shown its effectiveness in reducing the bacterial load and promoting wound healing [36].

Clinical trials have mainly focused on the treatment of impetigo, a highly contagious skin infection primarily caused by S. aureus and S. pyogenes [37]. Ozenoxacin has demonstrated non-inferiority to other topical antibacterial agents, such as retapamulin and fusidic acid, in terms of clinical and microbiological cure rates. In these studies, ozenoxacin consistently exhibited high cure rates, ranging from 85% to 95%, within 5 to 7 days of treatment [38].

Additionally, its efficacy against MRSA and penicillin-resistant S. pyogenes has been demonstrated, making it a valuable therapeutic option for infections caused by resistant pathogens. Secondary skin infections, such as those associated with eczema, have also been investigated in clinical trials [39]. Ozenoxacin has shown promise in reducing bacterial load and improving clinical symptoms in patients with infected atopic dermatitis. Furthermore, its safety and tolerability profile have been favorable, with the most common adverse events being mild and transient, such as application site reactions [40].

Emerging Applications of Ozenoxacin

While the primary focus of ozenoxacin’s clinical development has been on impetigo and other bacterial skin infections, its potent antibacterial activity against a broad range of pathogens has led to investigations into additional therapeutic applications. These include atypical mycobacterial infections, which are challenging to treat due to their inherent resistance to multiple antibiotics [41].

Preliminary studies have suggested that ozenoxacin may exhibit activity against certain atypical mycobacteria, making it a potential treatment option for these difficult-to-treat infections. Another area of interest is the potential use of ozenoxacin in the treatment of acne and rosacea. While these conditions are primarily inflammatory, bacterial overgrowth can exacerbate symptoms and contribute to treatment resistance [42].

Ozenoxacin’s potent activity against Cutibacterium acnes, formerly known as Propionibacterium acnes, may offer a new therapeutic approach for patients with acne who have not responded to traditional treatments. Prophylactic use of ozenoxacin in surgical site infections is another potential application under investigation. Topical application of the agent to the surgical site may help reduce bacterial colonization and prevent postoperative infections, particularly in cases where the patient is colonized with antibiotic-resistant bacteria. Finally, the use of ozenoxacin in special populations, such as pediatric and geriatric patients, is being explored [43].

Its favorable safety profile and low systemic absorption make it an attractive option for treating skin infections in these vulnerable groups, who may be at higher risk for adverse effects from systemic antibiotics [44]

Challenges and Future Perspectives

Despite the promising results seen with ozenoxacin, there are several challenges and areas for future research. Monitoring and managing resistance to ozenoxacin is crucial to preserving its clinical utility. Regular surveillance of resistance patterns and judicious use of the agent can help mitigate the risk of resistance development.

Advancements in formulation and delivery may also improve the effectiveness and ease of use of ozenoxacin. Novel formulations, such as hydrogels or nanoparticles, could enhance penetration into the skin and provide sustained release of the drug, potentially improving treatment outcomes.

Expanding the indications for ozenoxacin is another important area of research. As more evidence is gathered for its efficacy in various skin infections and other conditions, regulatory approval for these additional indications may be pursued.

Lastly, the potential for combination therapy with ozenoxacin warrants further exploration. Combining ozenoxacin with other antimicrobial agents or adjunctive therapies, such as anti-inflammatory drugs, may provide synergistic effects and improve treatment outcomes.

CONCLUSION

In conclusion, ozenoxacin represents a promising new addition to the arsenal of antibacterial agents available for the treatment of bacterial skin infections. Its unique pharmacological properties, broad-spectrum activity, and favorable safety profile make it an attractive therapeutic option, particularly in cases involving antibiotic-resistant pathogens. Emerging applications, such as the treatment of atypical mycob acterial infections, acne, rosacea, and prophylactic use in surgical site infections, further highlight its potential versatility and clinical utility.

However, to fully realize the potential benefits of ozenoxacin, it is crucial to address the challenges and areas for future research outlined in this review. Effective resistance monitoring and management, advancements in formulation and delivery, expansion of approved indications, and exploration of combination therapies are all important avenues to pursue.

As more evidence is gathered through clinical trials and real-world experience, the role of ozenoxacin in the management of bacterial skin infections will continue to evolve. Its potential to improve treatment outcomes, particularly for patients with antibiotic-resistant infections, underscores the importance of ongoing research and development in this area. Healthcare providers should remain up-to-date on the latest evidence and be prepared to incorporate ozenoxacin into their clinical practice when appropriate, guided by the principles of antibiotic stewardship to ensure its long-term effectiveness.

In summary, ozenoxacin offers a promising new approach to the treatment of bacterial skin infections, with the potential to address some of the challenges posed by antibiotic resistance. Continued research and clinical experience will help refine our understanding of its optimal use, ensuring that patients with skin infections receive the best possible care in the face of a rapidly evolving microbial landscape.

REFERENCES

1. Morrissey, I., Cantón, R., Vila, J., Gargallo-Viola, D., Zsolt, I., Garcia-Castillo, M., & López, Y. (2019). Microbiological profile of ozenoxacin. Future Microbiology, 14(9), 773-787.
2. Zhanel, G. G., Adam, H. J., Baxter, M., Lagace-Wiens, P. R., & Karlowsky, J. A. (2021). In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007–18). Journal of Antimicrobial Chemotherapy, 76(7), 1808-1814.
3. Lei, J., Ding, Y., Zhou, H. Y., Gao, X. Y., Cao, Y. H., Tang, D. Y., … & Chen, Z. Z. (2022). Practical synthesis of quinolone drugs via a novel TsCl-mediated domino reaction sequence. Green Chemistry, 24(15), 5755-5759.
4. Kong, W., Mao, W., Zhang, L., & Wu, Y. (2022). Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS). Frontiers in pediatrics, 10.
5. Gahlawat, G., Tesfaye, W., Bushell, M., Abrha, S., Peterson, G. M., Mathew, C., … & Thomas, J. (2021). Emerging treatment strategies for impetigo in endemic and nonendemic settings: a systematic review. Clinical therapeutics, 43(6), 986-1006.
6. Canton, R., Vila, J., Lopez, Y., Hebert, A. A., Tato, M., Garcia-Castillo, M., … & Zsolt, I. (2019, October). Ozenoxacin, a novel nonfluorinated quinolone for impetigo treatment: Its activity in resistant isolates involved in superficial skin infections. In JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (Vol. 81, No. 4, pp. AB249-AB249). 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA: MOSBY-ELSEVIER.
7. Lei, J., Ding, Y., Zhou, H. Y., Gao, X. Y., Cao, Y. H., Tang, D. Y., … & Chen, Z. Z. (2022). Practical synthesis of quinolone drugs via a novel TsCl-mediated domino reaction sequence. Green Chemistry, 24(15), 5755-5759.
8. Bonamonte, D., De Marco, A., Giuffrida, R., Conforti, C., Barlusconi, C., Foti, C., & Romita, P. (2020). Topical antibiotics in the dermatological clinical practice: Indications, efficacy, and adverse effects. Dermatologic Therapy, 33(6), e13824.
9. Sahu, J. K., & Mishra, A. K. (2019). Ozenoxacin: a novel drug discovery for the treatment of impetigo. Current Drug Discovery Technologies, 16(3), 259-264.
10. Jena, A. K., Sahoo, A., & Panda, M. (2022). Newly introduced repurposing topical ozenoxacin against grade-II acne vulgaris: a case series. Journal of the Egyptian Women’s Dermatologic Society, 19(2), 141.
11. Dyary, H. O., Faraj, G. J., & Saeed, N. M. (2023). History, Current Situation, and Future Perspectives on Antibiotics and Antibiotic Resistance. One Health Triad, Unique Scientific Publishers, Faisalabad, Pakistan, 2, 109-118.
12. Hiremath, L., Patil, S. J., & Pramod, T. Bioactive Molecules against Infectious Diseases: Current Concepts & Updates.
13. Han, Y., Ma, Y., Yao, S., Zhang, J., & Hu, C. (2021). In vivo and in silico evaluations of survival and cardiac developmental toxicity of quinolone antibiotics in zebrafish embryos (Danio rerio). Environmental Pollution, 277, 116779.
14. Cui, X., Lü, Y., & Yue, C. (2021). Development and research progress of anti-drug resistant bacteria drugs. Infection and drug resistance, 5575-5593.
15. Raju, B., Narendra, G., Verma, H., Kumar, M., Sapra, B., Kaur, G., … & Silakari, O. (2022). Machine learning enabled structure-based drug repurposing approach to identify potential CYP1B1 inhibitors. ACS omega, 7(36), 31999-32013.
16. López, Y., Tato, M., Gargallo-Viola, D., Cantón, R., Vila, J., & Zsolt, I. (2020). Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA. International journal of antimicrobial agents, 56(3), 106082.
17. Kurokawa, I., Kanayama, S., & Yamasaki, O. (2022). Antimicrobial activity of ozenoxacin and other antimicrobials against Staphylococcus aureus strains isolated from clinical skin specimens in Japan in 2019 and 2020. Journal of Infection and Chemotherapy, 28(12), 1693-1696.
18. Koulenti, D., Xu, E., Yin Sum Mok, I., Song, A., Karageorgopoulos, D. E., Armaganidis, A., … & Tsiodras, S. (2019). Novel antibiotics for multidrug-resistant gram-positive microorganisms. Microorganisms, 7(8), 270.
19. Jena, A. K., Sahoo, A., & Panda, M. (2022). Newly introduced repurposing topical ozenoxacin against grade-II acne vulgaris: a case series. Journal of the Egyptian Women’s Dermatologic Society, 19(2), 141.
20. Rayadurgam, J., Sana, S., Sasikumar, M., & Gu, Q. (2021). Palladium catalyzed C–C and C–N bond forming reactions: an update on the synthesis of pharmaceuticals from 2015–2020. Organic Chemistry Frontiers, 8(2), 384-414.
21. Morrissey, I., Cantón, R., Vila, J., Gargallo-Viola, D., Zsolt, I., Garcia-Castillo, M., & López, Y. (2019). Microbiological profile of ozenoxacin. Future Microbiology, 14(9), 773-787.
22. Eudaley, S. (2020). Ozenoxacin (Xepi) for the Treatment of Impetigo. American Family Physician, 101(12), 760-761.
23. Esposito, S. M., Kwong, P. C., FAAD, I., & FAAD, M. (2021). Do antimicrobial resistance patterns matter? An algorithm for the treatment of patients with impetigo. Journal of drugs in dermatology, 20(2), 134-142.
24. Davino, G., D’Alvano, T., & Esposito, S. (2020). The Use of Ozenoxacin in Pediatric Patients: Clinical Evidence, Efficacy and Safety. Frontiers in Pharmacology, 11, 559708.
25. Torrelo, A., Grimalt, R., Masramon, X., Albareda López, N., & Zsolt, I. (2020). Ozenoxacin, a new effective and safe topical treatment for impetigo in children and adolescents. Dermatology, 236(3), 199-207.
26. Kurokawa, I., Kanayama, S., & Yamasaki, O. (2022). Antimicrobial activity of ozenoxacin and other antimicrobials against Staphylococcus aureus strains isolated from clinical skin specimens in Japan in 2019 and 2020. Journal of Infection and Chemotherapy, 28(12), 1693-1696.
27. López, Y., Tato, M., Gargallo-Viola, D., Cantón, R., Vila, J., & Zsolt, I. (2020). Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA. International Journal of Antimicrobial Agents, 56(3), 106082.
28. López, Y., Muñoz, L., Gargallo-Viola, D., Cantón, R., Vila, J., & Zsolt, I. (2021). Uptake of ozenoxacin and other quinolones in gram-positive bacteria. International Journal of Molecular Sciences, 22(24), 13363.
29. Sultana, N., Siddique, M. M. R., Khanam, R., & Sharmin, S. (2023). Efficacy and Safety of Ozenoxacin in the Treatment of Bacterial Skin Diseases in Adult and Paediatric Patients. Sch J App Med Sci, 3, 614-619.
30. Ron, G. G., & Arranz, M. V. (2022). New therapeutic applications of ozenoxacin in superficial skin infections. Dermatology Reports, 14(2).
31. Zhanel, G. G., Adam, H. J., Baxter, M., Lagace-Wiens, P. R., & Karlowsky, J. A. (2021). In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007–18). Journal of Antimicrobial Chemotherapy, 76(7), 1808-1814.
32. Jena, A. K., Sahoo, A., & Panda, M. (2022). Newly introduced repurposing topical ozenoxacin against grade-II acne vulgaris: a case series. Journal of the Egyptian Women’s Dermatologic Society, 19(2), 141.
33. Eudaley, S. (2020). Ozenoxacin (Xepi) for the Treatment of Impetigo. American Family Physician, 101(12), 760-761.
34. Hebert, A. A., Rosen, T., López, N. A., Zsolt, I., & Masramon, X. (2020). Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo. International Journal of Women’s Dermatology, 6(2), 109-115.
35. Gelmetti, C., Boccaletti, V., Amadori, A., & Bosis, S. (2020). Topical treatment of impetigo with ozenoxacin in children. European Journal of Pediatric Dermatology, 30(2), 95-103.
36. Quintosa, J. R., Ago, C. C., Mainar, A. S., Villoro, R., & Pérez-Román, I. (2022). Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain. Global & Regional Health Technology Assessment, 9(1), 133-137.
37. Shirsat, A., Shah, B., & Trailokya, A. Ozenoxacin: A novel topical quinolone.
38. Galindo, E., & Hebert, A. A. (2021). A comparative review of current topical antibiotics for impetigo. Expert Opinion on Drug Safety, 20(6), 677-683.
39. Barbieri, E., Cavagnis, S., Boracchini, R., Scamarcia, A., Testa, A., Ciarniello, M. G., … & Cantarutti, A. (2023). Retrospective Analysis of the Real-World Use of Topical Antimicrobials in the Paediatric Population with Impetigo in Italy: Focus on the Role of Ozenoxacin 1% Cream. Children, 10(3), 547.
40. Koulenti, D., Xu, E., Yin Sum Mok, I., Song, A., Karageorgopoulos, D. E., Armaganidis, A., … & Tsiodras, S. (2019). Novel antibiotics for multidrug-resistant gram-positive microorganisms. Microorganisms, 7(8), 270.
41. Vila, J., Hebert, A. A., Torrelo, A., López, Y., Tato, M., García-Castillo, M., & Cantón, R. (2019). Ozenoxacin: a review of preclinical and clinical efficacy. Expert review of anti-infective therapy, 17(3), 159-168.
42. O’Sullivan, J. N., Rea, M. C., Hill, C., & Ross, R. P. (2020). Protecting the outside: Biological tools to manipulate the skin microbiota. FEMS Microbiology Ecology, 96(6), fiaa085.
43. Hiremath, L., Patil, S. J., & Pramod, T. Bioactive Molecules against Infectious Diseases: Current Concepts & Updates.
44. AbuBaih, R. H., Fawzy, M. A., & Nazmy, M. H. (2023). The prospective potential of fluoroquinolones as anticancer agents. Journal of Modern Research, 5(1), 4-10.